X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1136) 1136
Publication (151) 151
Conference Proceeding (40) 40
Book / eBook (14) 14
Book Chapter (12) 12
Book Review (11) 11
Newspaper Article (9) 9
Magazine Article (6) 6
Dissertation (3) 3
Data Set (2) 2
Reference (2) 2
Trade Publication Article (2) 2
Patent (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (429) 429
index medicus (371) 371
male (298) 298
female (268) 268
adult (144) 144
animals (126) 126
research (120) 120
middle aged (113) 113
neurosciences (100) 100
aged (86) 86
adolescent (78) 78
analysis (74) 74
health aspects (67) 67
young adult (67) 67
studies (64) 64
risk factors (63) 63
care and treatment (61) 61
usage (58) 58
dopamine (57) 57
hematology (57) 57
oncology (56) 56
medicine (54) 54
psychiatry (53) 53
research article (53) 53
genetic aspects (52) 52
mutation (52) 52
cancer (51) 51
infant, newborn (50) 50
pharmacology & pharmacy (50) 50
rats (49) 49
immunology (48) 48
integral equations (46) 46
medicine and health sciences (46) 46
treatment outcome (45) 45
physiological aspects (44) 44
multidisciplinary sciences (43) 43
sport sciences (43) 43
cardiac & cardiovascular systems (41) 41
child (41) 41
expression (41) 41
proteins (41) 41
abridged index medicus (39) 39
management (39) 39
surgery (37) 37
mathematics (36) 36
mice (36) 36
pediatrics (36) 36
diagnosis (35) 35
biology and life sciences (34) 34
mathematics, applied (34) 34
time factors (34) 34
aged, 80 and over (32) 32
dendritic cells (32) 32
science (32) 32
article (31) 31
reward (31) 31
risk (31) 31
scattering (31) 31
double-blind method (30) 30
genes (30) 30
methods (30) 30
cell biology (29) 29
genetics (29) 29
infant (29) 29
prefrontal cortex (29) 29
rehabilitation (29) 29
genetics & heredity (28) 28
life sciences (28) 28
medicine, general & internal (28) 28
patients (28) 28
shoulder (28) 28
prospective studies (27) 27
drug therapy (26) 26
gene expression (26) 26
mortality (26) 26
prevalence (26) 26
rats, wistar (26) 26
children (25) 25
disease (25) 25
engineering, electrical & electronic (25) 25
follow-up studies (25) 25
infant, premature (25) 25
medical research (25) 25
pharmacology (25) 25
biochemistry & molecular biology (24) 24
child, preschool (24) 24
electromagnetic scattering (24) 24
infants (24) 24
laboratories (24) 24
leukemia (24) 24
stroke (24) 24
algorithms (23) 23
behavior (23) 23
belgium (23) 23
clinical neurology (23) 23
parkinsons-disease (23) 23
antennas (22) 22
dendritic cells - immunology (22) 22
magnetic resonance imaging (22) 22
original (22) 22
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 09/2017, Volume 377, Issue 12, pp. 1119 - 1131
Patients with myocardial infarction and a high-sensitivity CRP level of 2 mg or more per liter were assigned to one of three canakinumab doses or placebo. The... 
C-REACTIVE PROTEIN | MEDICINE, GENERAL & INTERNAL | HEART-DISEASE | MYOCARDIAL-INFARCTION | STATIN THERAPY | CLONAL HEMATOPOIESIS | INFLAMMATION | CARDIOVASCULAR-DISEASE | INTERLEUKIN-1-BETA INHIBITION | RISK | CORONARY-ARTERY-DISEASE | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Male | Secondary Prevention | Infection - etiology | Incidence | Dose-Response Relationship, Drug | Anti-Inflammatory Agents - adverse effects | C-Reactive Protein - metabolism | Lipids - blood | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Anti-Inflammatory Agents - administration & dosage | Female | Neutropenia - chemically induced | Interleukin-1beta - antagonists & inhibitors | Stroke - prevention & control | Atherosclerosis - drug therapy | Double-Blind Method | Interleukin-1beta - immunology | Atherosclerosis - blood | Myocardial Infarction - drug therapy | Antibodies, Monoclonal - administration & dosage | Aged | Myocardial Infarction - prevention & control | Myocardial infarction | Cerebral infarction | Stroke | Heart attacks | C-reactive protein | Cytokines | Clinical trials | Cardiovascular disease | Innate immunity | Inflammation | Angina | Angina pectoris | Thrombosis | Cholesterol | Disease prevention | Proteins | Arteriosclerosis | Atherosclerosis | Cardiovascular diseases | Health risk assessment | Drug therapy | Drug dosages | Klinisk medicin | Clinical Medicine
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2019, Volume 380, Issue 4, pp. 347 - 357
In a randomized trial of patients with type 2 diabetes, treatment with dapagliflozin, an SGLT2 inhibitor that promotes glucosuria, did not result in a higher... 
2013 ACCF/AHA GUIDELINE | MEDICINE, GENERAL & INTERNAL | SELECTIVE SGLT2 INHIBITOR | MANAGEMENT | HEART-FAILURE OUTCOMES | DISEASE | AMERICAN-COLLEGE | ASSOCIATION TASK-FORCE | KIDNEY | EMPAGLIFLOZIN | SOCIETY | Cardiovascular Diseases - etiology | Sodium-Glucose Transporter 2 Inhibitors - therapeutic use | Sodium-Glucose Transporter 2 Inhibitors - adverse effects | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Hospitalization - statistics & numerical data | Male | Benzhydryl Compounds - adverse effects | Cardiovascular Diseases - mortality | Female | Glucosides - therapeutic use | Aged | Diabetes Mellitus, Type 2 - drug therapy | Benzhydryl Compounds - therapeutic use | Heart Failure - epidemiology | Diabetes Mellitus, Type 2 - complications | Glucosides - adverse effects | Type 2 diabetes | Safety and security measures | Dapagliflozin | Dosage and administration | Drug therapy | Cardiovascular diseases | Risk factors | Heart failure | Myocardial infarction | Cerebral infarction | End-stage renal disease | Heart attacks | Mortality | Diabetes mellitus | Cardiovascular disease | FDA approval | Patients | Glomerular filtration rate | Heart rate | Ischemia | Sodium | Arteriosclerosis | Ketoacidosis | Death | Diabetes | Kidney diseases | Safety | Diabetes mellitus (non-insulin dependent) | Heart diseases
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2015, Volume 372, Issue 19, pp. 1791 - 1800
Patients with myocardial infarction 1 to 3 years previously were assigned to ticagrelor, 90 or 60 mg twice daily, or to placebo, in addition to low-dose... 
MEDICINE, GENERAL & INTERNAL | HEART-DISEASE | CLOPIDOGREL | MANAGEMENT | ESC GUIDELINES | AMERICAN-COLLEGE | PREVENTION | ASSOCIATION TASK-FORCE | ACUTE CORONARY SYNDROMES | PRASUGREL | ASPIRIN | Purinergic P2Y Receptor Antagonists - administration & dosage | Double-Blind Method | Drug Administration Schedule | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Kaplan-Meier Estimate | Male | Risk | Secondary Prevention | Adenosine - administration & dosage | Aspirin - administration & dosage | Purinergic P2Y Receptor Antagonists - adverse effects | Myocardial Infarction - drug therapy | Adenosine - adverse effects | Adenosine - analogs & derivatives | Intracranial Hemorrhages - chemically induced | Platelet Aggregation Inhibitors - administration & dosage | Cardiovascular Diseases - mortality | Female | Aged | Hemorrhage - chemically induced | Drug Therapy, Combination | Platelet Aggregation Inhibitors - adverse effects | Dose-response relationship (Biochemistry) | Treatment outcome | Care and treatment | Safety and security measures | Analysis | Dosage and administration | Ticagrelor | Heart attack | Risk factors | Myocardial infarction | Cerebral infarction | Aspirin | Stroke | Heart attacks | Hemorrhage | Long term | Patients | Thrombolysis | Bleeding | Blood platelets | Antagonist drugs | Cardiovascular diseases | Drug therapy | Life Sciences | Human health and pathology
Journal Article